Navigation Links
ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance
Date:5/2/2008

tements about future financial and operating results and liquidity needs, anticipated revenue synergies and cost savings as a result of ev3's acquisition of FoxHollow and the timing thereof, anticipated expenses as a result of ev3's acquisition of FoxHollow and the timing thereof, effects of recent U.S. peripheral vascular sales force restructuring activities, new product benefits and market acceptance, and other statements identified by words such as "expect," "anticipate," "will," "may," "believe," "could," "outlook," "guidance," or words of similar meaning and any other statements that are not historical facts. Such forward-looking statements are based upon the current beliefs and expectations of ev3's management and are inherently subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Such potential risks and uncertainties include, but are not limited to, in no particular order: the failure to achieve profitability within expected time periods, the failure to realize revenue synergies and cost-savings from ev3's acquisition of FoxHollow, the closure of its Redwood City facility or delay in realization thereof; the businesses of ev3 and FoxHollow not being integrated successfully, or such integration taking longer or being more difficult, time- consuming or costly to accomplish than expected; the impact of competitive products and pricing; changes in the regulatory environment; availability of third party reimbursement; potential margin pressure resulting from volume selling, as well as potential adverse effects on future product demand resulting from volume purchases; delays in regulatory approvals and the introduction of new products; market acceptance of new products and success of clinical testing. More detailed information on these and additional factors which could affect ev3's operating and financial results is described in the company's filings with the Securities and Exchange Commission, i
'/>"/>
SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. United Therapeutics Reports First Quarter 2008 Financial Results
2. Endocare Reports 2008 First Quarter Financial Results
3. AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
4. LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
5. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
6. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
7. Alexion Reports First Quarter 2008 Results
8. Masimo Reports First Quarter 2008 Financial Results
9. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
10. Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth
11. SuperGen Reports 2008 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... NY , April 23, 2015 /PRNewswire/ - Crystal ... an Executive Informational Overview ® (EIO) on Aeterna ... 52-page report is available on Crystal Research Associates, website ... on Aeterna Zentaris, website at www.aezsinc.com . ... into a specialty biopharmaceutical company in oncology, endocrinology, and ...
(Date:4/23/2015)... 2015 Delpor, Inc. (Delpor), a biotechnology ... United States Patent and Trademark Office has issued 2 ... technology. US Pat. No. 8,986,727 was issued on ... delivery device for the sustained release of therapeutic ... the sustained (zero-order) release of large and small molecules ...
(Date:4/22/2015)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ) today reported ... For the first quarter ended March 31, 2015, ... or $0.08 per share, compared to a net loss ... same period in 2014. As of March 31, 2015, ... interest receivable of $226.1 million. Revenues for ...
(Date:4/22/2015)... SEATTLE , April 22, 2015   ... startup, today announced $1.6M in Series A financing ... investor. The funding helps accelerate consumer and employer ... scores covering surgeries at over 4,800 U.S. hospitals. ... surgery, you are probably very concerned about choosing ...
Breaking Biology Technology:Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 3Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 2Sangamo BioSciences Reports First Quarter 2015 Financial Results 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 4Sangamo BioSciences Reports First Quarter 2015 Financial Results 5Sangamo BioSciences Reports First Quarter 2015 Financial Results 6Sangamo BioSciences Reports First Quarter 2015 Financial Results 7Sangamo BioSciences Reports First Quarter 2015 Financial Results 8MPIRICA Health Inc. Secures $1.6M to Promote FICO-Like Quality Scores for Surgeries 2
... Sciences Inc., a privately held,biopharmaceutical company that specializes ... pharmaceuticals, today reported,that enrollment has begun for a ... Iluvien(TM) in patients with bilateral geographic atrophy (GA) ... The pilot study will ...
... Dec. 11 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), ... for the early detection of diseases and personalized ... into a agreement allowing Centocor Research & Development, ... genomic biomarker program. Additional terms of the agreement ...
... LOURES, Portugal, December 11 Hovione announced today,that it ... Ingredients (API) site in Ireland. This site manufactures,intermediates for ... The site has had a number of ... & Welch, Warner Lambert, Pfizer and now Hovione. Over,the ...
Cached Biology Technology:Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD 2GeneNews provides Centocor access to its osteoarthritis program 2Hovione Buys Pfizer's Loughbeg API Facility 2Hovione Buys Pfizer's Loughbeg API Facility 3
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... Reusing the major greenhouse gas carbon dioxide (CO2) from industrial ... environment is on the verge of becoming a commercial ... in the U.S. are leading the way, according to an ... newsmagazine of the American Chemical Society. Alex Scott, C&EN,s ...
... contact during early infancy may be a key to early ... National Institute of Mental Health (NIMH), part of the National ... Nature , the study reveals the earliest sign of developing ... within the first two to six months of life. ...
... Texas Medical Branch at Galveston have discovered one of the ... the Journal of Biological Chemistry . While ... cardiomyopathy develops is not well understood, other than that it ... a family of enzymes that controls the functions of other ...
Cached Biology News:Earliest marker for autism found in young infants 2Earliest marker for autism found in young infants 3Research reveals possible cause of diabetic cardiomyopathy 2
FITC~Bovine Serum Albumin...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
GEL FILTRATION CAL KIT HMW, 1 EA. *Category: Gel Filtration Gels....
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
Biology Products: